Literature DB >> 12787826

Pharmacological sensitivity and gene expression analysis of the tibial nerve injury model of neuropathic pain.

Heiko A Hofmann1, Jean De Vry, Angela Siegling, Peter Spreyer, Dirk Denzer.   

Abstract

The tibial nerve injury model is a novel, surgically uncomplicated, rat model of neuropathic pain based on a unilateral transection (neurotomy) of the tibial branch of the sciatic nerve. The aim of the present study was to describe some behavioral and molecular features of the model, and to test its sensitivity to a number of drugs which are currently used for the treatment of neuropathic pain. The model was characterized by a pronounced mechanical allodynia which was present in all subjects and a less robust thermal hyperalgesia. Mechanical allodynia developed within 2 weeks post-surgery and was reliably present for at least 9 weeks. Neurotomized rats showed no autotomy and their body weight developed normally. Gene expression in ipsilateral L5 dorsal root ganglia, analyzed by quantitative polymerase chain reaction (PCR), showed a pronounced up-regulation of galanin and vasointestinal peptide (VIP). This up-regulation developed rapidly (within 1 to 2 days following neurotomy) and remained present for at least 12 days. On the other hand, expression of calcitonin gene-related peptide (CGRP) and substance P mRNA was down-regulated 12 days following neurotomy. Mechanical allodynia was completely reversed by morphine [minimal effective dose (MED): 8 mg/kg, i.p.] and partially reversed by carbamazepine (MED: 64 mg/kg, i.p.), baclofen (MED: 3 mg/kg, i.p.) and amitriptyline (trend for efficacy at 32 mg/kg, i.p.), but not by gabapentin (50-100 mg/kg, i.p.). The finding that the tibial nerve injury model shows a robust and persistent mechanical allodynia which is sensitive to a number of established analgesics, as well as a gene expression profile which is compatible with that obtained in other models of neuropathic pain, further supports its validity as a reliable and surgically uncomplicated model for the study of neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12787826     DOI: 10.1016/s0014-2999(03)01753-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  17 in total

1.  Time course of substance P expression in dorsal root ganglia following complete spinal nerve transection.

Authors:  Wendy Weissner; Barbara J Winterson; Alan Stuart-Tilley; Marshall Devor; Geoffrey M Bove
Journal:  J Comp Neurol       Date:  2006-07-01       Impact factor: 3.215

2.  Metabolomics implicates altered sphingolipids in chronic pain of neuropathic origin.

Authors:  Gary J Patti; Oscar Yanes; Leah P Shriver; Jean-Phillipe Courade; Ralf Tautenhahn; Marianne Manchester; Gary Siuzdak
Journal:  Nat Chem Biol       Date:  2012-01-22       Impact factor: 15.040

3.  Pharmacological and behavioral characterization of the saphenous chronic constriction injury model of neuropathic pain in rats.

Authors:  Ozgur Gunduz; Cagatay Oltulu; Rabia Guven; Dilek Buldum; Ahmet Ulugol
Journal:  Neurol Sci       Date:  2011-09-10       Impact factor: 3.307

4.  Inhibition of neuropathic hyperalgesia by intrathecal bone marrow stromal cells is associated with alteration of multiple soluble factors in cerebrospinal fluid.

Authors:  Gregory Fischer; Fei Wang; Hongfei Xiang; Xiaowen Bai; Hongwei Yu; Quinn H Hogan
Journal:  Exp Brain Res       Date:  2017-06-01       Impact factor: 1.972

5.  Early dexamethasone treatment after implantation of a sciatic-nerve cuff decreases the concentration of substance P in the lumbar spinal cord of rats with neuropathic pain.

Authors:  Francis Beaudry; Christiane Girard; Pascal Vachon
Journal:  Can J Vet Res       Date:  2007-04       Impact factor: 1.310

Review 6.  Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside.

Authors:  Elizabeth J Rahn; Andrea G Hohmann
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

Review 7.  Behavioral models of pain states evoked by physical injury to the peripheral nerve.

Authors:  Linda S Sorkin; Tony L Yaksh
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

8.  Alterations in Spinal Cord Metabolism during Treatment of Neuropathic Pain.

Authors:  Caroline H Johnson; Gary J Patti; Jean-Philippe Courade; Leah P Shriver; Linh T Hoang; Marianne Manchester; Gary Siuzdak
Journal:  J Neuroimmune Pharmacol       Date:  2015-08-02       Impact factor: 4.147

9.  Microphthalmia, parkinsonism, and enhanced nociception in Pitx3 ( 416insG ) mice.

Authors:  Michael Rosemann; Alesia Ivashkevich; Jack Favor; Claudia Dalke; Sabine M Hölter; Lore Becker; Ildikó Rácz; Ines Bolle; Martina Klempt; Birgit Rathkolb; Svetoslav Kalaydjiev; Thure Adler; Antonio Aguilar; Wolfgang Hans; Marion Horsch; Jan Rozman; Julia Calzada-Wack; Sandra Kunder; Beatrix Naton; Valerie Gailus-Durner; Helmut Fuchs; Holger Schulz; Johannes Beckers; Dirk H Busch; J Peter H Burbach; Marten P Smidt; Leticia Quintanilla-Martinez; Irene Esposito; Thomas Klopstock; Martin Klingenspor; Markus Ollert; Eckhard Wolf; Wolfgang Wurst; Andreas Zimmer; Martin Hrabé de Angelis; Michael Atkinson; Ulrich Heinzmann; Jochen Graw
Journal:  Mamm Genome       Date:  2009-12-22       Impact factor: 2.957

10.  ATF3-Expressing Large-Diameter Sensory Afferents at Acute Stage as Bio-Signatures of Persistent Pain Associated with Lumbar Radiculopathy.

Authors:  Jiann-Her Lin; Yu-Wen Yu; Yu-Chia Chuang; Cheng-Han Lee; Chih-Cheng Chen
Journal:  Cells       Date:  2021-04-23       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.